TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21307846

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 24
Study: 19593240

Group type: EXPERIMENTAL
Intervention: Low vision rehabilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 24
Study: 17188087

Group type: EXPERIMENTAL
Intervention: 2.5% talactoferrin gel
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 8.5% talactoferrin gel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15536575

Group type: EXPERIMENTAL
Intervention: Study solution (2 mg of morphine, 15 mg of bupivacaine, 80 mg of methylprednisolone, and 0.05 mg of adrenaline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 40
Study: 10767223

Group type: EXPERIMENTAL
Intervention: Montelukast alone, 10 mg (ML(10))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol alone, 50 microg (SM(50))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) and salmeterol (50 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) and inhaled salmeterol, 100 microg (SM(100))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo inhaler and tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapies vs ML(10) alone
Number of subjects: 12
Study: 9067044

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms iv
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline bolus iv
Number of subjects: 60
Study: 8354335

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Simvastatin and Pravastatin
Number of subjects: 23
Study: 2942886

Group type: EXPERIMENTAL
Intervention: PCNG (30 mg applied 30 minutes before induction)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 23
Study: 31697801

Group type: EXPERIMENTAL
Intervention: Emicizumab 1.5 mg/kg weekly (group A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Emicizumab 3 mg/kg every 2 weeks (group B)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Emicizumab 6 mg/kg every 4 weeks (group C)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Emicizumab prophylaxis (intraindividual comparison)
Number of subjects: 85
Study: 28148685

Group type: EXPERIMENTAL
Intervention: 57FePP+ZnSO4
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 57FePP+ZnO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 57FePP-Zn
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Relative iron bioavailability from 57FePP+ZnSO4
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Relative iron bioavailability from 57FePP-Zn
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Relative iron bioavailability from 57FePP+ZnO
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In vitro solubility from 57FePP+ZnSO4
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: In vitro solubility from 57FePP+ZnO
Number of subjects: 19
Study: 25856686

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg subcutaneously every 12 hours
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.5 mg/kg subcutaneously every 24 hours
Number of subjects: 65
Study: 23725394

Group type: EXPERIMENTAL
Intervention: Coflex Interlaminar Stabilization
Number of subjects: 150

Group type: COMPARATOR
Intervention: Posterolateral spinal fusion (PSF)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 22080240

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 73
Study: 19936044

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 5531
Study: 18037713

Group type: EXPERIMENTAL
Intervention: Curd (dahi)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leaf Protein Concentrate (LPC)
Number of subjects: 80
Study: 15521877

Group type: EXPERIMENTAL
Intervention: Epididymal sperm recovery (Group E)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Testicular sperm recovery (Group T)
Number of subjects: 151
Study: 11519776

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/d
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg/d
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg/d
Number of subjects: 53

Group type: COMPARATOR
Intervention: lansoprazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: rabeprazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: pantoprazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: omeprazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: PPIs
Number of subjects: 53
Study: 9710365

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 12
Study: 7986182

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered sumatriptan succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second injection of subcutaneously administered sumatriptan succinate
Number of subjects: 0
Study: 2645969

Group type: EXPERIMENTAL
Intervention: Voltaren
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ketogan
Number of subjects: 56
Study: 31900579

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/day for 20 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29223575

Group type: COMPARATOR
Intervention: TIVA (Propofol and dexmedetomidine)
Number of subjects: 100
Study: 28898870

Group type: EXPERIMENTAL
Intervention: Vitamin D3 buccal spray 800 IU/daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral drops 750 IU/daily
Number of subjects: 24
Study: 26347918

Group type: EXPERIMENTAL
Intervention: Complete revascularisation guided by FFR values
Number of subjects: 627

Group type: COMPARATOR
Intervention: No further invasive treatment after primary PCI of the infarct-related artery only
Number of subjects: 627
Study: 23832582

Group type: EXPERIMENTAL
Intervention: GSK1995057 intravenous infusion (0.0004, 0.002, and 0.01 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GSK1995057 intravenous infusion
Number of subjects: 28
Study: 21827052

Group type: EXPERIMENTAL
Intervention: Miniscrew with Class III traction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 20
Study: 19142662

Group type: EXPERIMENTAL
Intervention: Increased recreational physical activity (3 times/week for 12 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (maintained same level of physical activity)
Number of subjects: 76
Study: 17074624

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single steroid injection
Number of subjects: 40
Study: 14872153

Group type: EXPERIMENTAL
Intervention: Increased awareness of hypertension risk and early intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic medicine and candidate single nucleotide polymorphisms
Number of subjects: 0
Study: 11696141

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl by bolus technique (Group 1, n=8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl by continuous infusion (Group 2, n=6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam infusion (Group 3, n=5)
Number of subjects: 19
Study: 9140018

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-20098 (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-20098 (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8173562

Group type: EXPERIMENTAL
Intervention: Outpatient individual and family psychotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Assessment interview only (control group)
Number of subjects: 90
Study: 3390962

Group type: EXPERIMENTAL
Intervention: Copal Digital Sphygmomanometer UA251
Number of subjects: 67
Study: 31540747

Group type: EXPERIMENTAL
Intervention: High tangent irradiation
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Treatment planning designs based on MA.20, EORTC, AMAROS and Z0011 trials
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Inclusion of axillary level II and extension of supraclavicular CTV
Number of subjects: 235

Group type: COMPARATOR
Intervention: None of the treatment plan designs
Number of subjects: 235
Study: 31383427

Group type: EXPERIMENTAL
Intervention: Baduanjin qigong training (exercise group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment group (control group)
Number of subjects: 60
Study: 28575729

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg daily (S5 group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metformin 1500mg daily (Met group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (lifestyle intervention only)
Number of subjects: 25
Study: 25816050

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24649781

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (10 ml bolus)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (control group)
Number of subjects: 32
Study: 17189218

Group type: EXPERIMENTAL
Intervention: GGCX 8016G>A GG genotype (n = 156)
Number of subjects: 3655

Group type: EXPERIMENTAL
Intervention: VKORC1 3730G>A and CALU 20943T>A genotypes
Number of subjects: 3655
Study: 14649215

Group type: EXPERIMENTAL
Intervention: Hormone therapy as an adjunct treatment for cardiovascular disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved hormone formulations and selective estrogen receptor modulators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Understanding of estrogen receptors in vascular tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing and dosing for therapeutic intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanisms of interactions between coagulation proteins, inflammatory cytokines, platelets and the vessel wall
Number of subjects: 0
Study: 10397660

Group type: EXPERIMENTAL
Intervention: High-dose fluticasone propionate (100 microg per nostril) 4 times daily for 6 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7746690

Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (3 doses at 2, 3, and 4 months)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (2 doses with shorter interval)
Number of subjects: 108
Study: 1772001

Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole 75 mg t.i.d and acetylsalicylic acid 330 mg t.i.d.
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 7042360

Group type: EXPERIMENTAL
Intervention: Indoprofen (200 mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29696990

Group type: EXPERIMENTAL
Intervention: Tailored, affordable technologies to improve mobility and physical activity
Number of subjects: 20
Study: 28652278

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day orally, 3 weeks on, 1 week off) + Fulvestrant (500 mg) + Goserelin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo + Fulvestrant (500 mg) + Goserelin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Palbociclib + Fulvestrant + Goserelin
Number of subjects: 108
Study: 26363433

Group type: EXPERIMENTAL
Intervention: Daily text messages
Number of subjects: 230

Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 230
Study: 23135760

Group type: EXPERIMENTAL
Intervention: ITF prebiotics (inulin/oligofructose 50/50 mix; 16 g/day for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study: 22112039

Group type: EXPERIMENTAL
Intervention: HEMA-free one-step adhesive G-Bond (GC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional three-step adhesive Optibond FL (Kerr)
Number of subjects: 52
Study: 17973945

Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: simvastatin (40 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: combination of ezetimibe and simvastatin
Number of subjects: 72
Study: 16025262

Group type: EXPERIMENTAL
Intervention: Amifostine 740 mg/m2
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 12681863

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 34
Study: 10493846

Group type: EXPERIMENTAL
Intervention: Supervised outpatient group-training programme (n=50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (n=51)
Number of subjects: 101
Study: 9092413

Group type: EXPERIMENTAL
Intervention: c7E3 (ReoPro)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific inhibitors (integrelin, lamifiban, tirofiban)
Number of subjects: 0
Study: 1788581

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: No anti-emetic prophylaxis
Number of subjects: 0
Study: 6119998

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.011 mg kg‐1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neostigmine (0.010 mg kg‐1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 29
Study: 31950307

Group type: EXPERIMENTAL
Intervention: Perceived partner support of PrEP use
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Perceived benefit of PrEP use
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Perceived partner support of PrEP and benefit of PrEP use
Number of subjects: 659
Study: 30897393

Group type: EXPERIMENTAL
Intervention: Self-stigma assessment
Number of subjects: 80
Study: 29176675

Group type: EXPERIMENTAL
Intervention: High-probability condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-probability condition
Number of subjects: 0
Study: 25662503

Group type: EXPERIMENTAL
Intervention: 4-mm pen needle (PN)
Number of subjects: 274
Study: 24571205

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-daily
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 22489544

Group type: EXPERIMENTAL
Intervention: Cooperative play in Halo II
Number of subjects: 0

Group type: COMPARATOR
Intervention: Competitive play in Halo II
Number of subjects: 0
Study: 19686113

Group type: EXPERIMENTAL
Intervention: 0.5% (w/w) monosodium L-glutamate (MSG) added to rice gruel, 3 times a day for 3 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.5% (w/w) monosodium L-glutamate (MSG)
Number of subjects: 29
Study: 17890515

Group type: EXPERIMENTAL
Intervention: Higher frequency of exposure
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Higher frequency of exposure coupled with informative context
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vocabulary lessons
Number of subjects: 34
Study: 15077088

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12148249

Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Peroxyborate (CHX + PER)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chlorhexidine alone (CHX)
Number of subjects: 28
Study: 9794022

Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cognitive and behaviour therapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Self-help
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study: 7895928

Group type: EXPERIMENTAL
Intervention: Omeprazole (8 mg/h after a bolus of 80 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Omeprazole (4 mg/h after a bolus of 80 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine (0.25 mg/kg/h after a bolus of 50 mg)
Number of subjects: 10
Study: 2142869

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 11
Study: 322836

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative radiotherapy
Number of subjects: 0
Study: 31582549

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 192

Group type: COMPARATOR
Intervention: No Granulocyte colony-stimulating factor (non-G-CSF)
Number of subjects: 192
Study: 31434781

Group type: EXPERIMENTAL
Intervention: Surgical treatment (laminectomy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-surgical treatment (structured physical training programme)
Number of subjects: 150
Study: 28084150

Group type: EXPERIMENTAL
Intervention: Progressive strength training (PRT) program, 3 times a week for 50 weeks (20 weeks supervised, 30 weeks home-based)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Home exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Progressive strength training (PRT) program
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Follow-up at 50 weeks
Number of subjects: 6
Study: 25773449

Group type: EXPERIMENTAL
Intervention: One Shape (rotary file system)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Reciproc (reciprocating file system)
Number of subjects: 624
Study: 23220856

Group type: EXPERIMENTAL
Intervention: Remifentanil dosage adjusted according to SPI
Number of subjects: 170

Group type: COMPARATOR
Intervention: Clinical parameters (Control)
Number of subjects: 170
Study: 21669894

Group type: EXPERIMENTAL
Intervention: Sucrose plus EMLA cream (S+E group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sucrose plus placebo cream (S group)
Number of subjects: 76
Study: 19368751

Group type: EXPERIMENTAL
Intervention: Cognitive and familial factors
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: View of self, view of the world, internal attributional style, need for social approval, positive problem-solving orientation, and family problems
Number of subjects: 439
Study: 16959024

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 15074090

Group type: EXPERIMENTAL
Intervention: Prednisone plus Zhuanyindan (ICWM group)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Zhuanyindan (TCM group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prednisone (WM group)
Number of subjects: 82
Study: 11526360

Group type: EXPERIMENTAL
Intervention: Bruce treadmill protocol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Modified Naughton treadmill protocol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Bicycle testing
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified Naughton protocol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bruce protocol (retrospective analysis)
Number of subjects: 15
Study: 9357385

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 micrograms
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study: 8253929

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both GTN and placebo
Number of subjects: 120
Study: 3956275

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-antagonist)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31490861

Group type: EXPERIMENTAL
Intervention: Early self-directed home exercise program (HEP) for 6 weeks with weekly supportive telephone calls
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 29717497

Group type: EXPERIMENTAL
Intervention: Helping/neutral condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hindering/neutral condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hinderer
Number of subjects: 0
Study: 27684290

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg oral dose
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Aripiprazole treatment
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Aripiprazole concentrations
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: AUC
Number of subjects: 157
Study: 24515927

Group type: EXPERIMENTAL
Intervention: Video games (n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional therapy (n = 14)
Number of subjects: 29
Study: 22252780

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 117
Study: 20335281

Group type: EXPERIMENTAL
Intervention: FTCQ-12
Number of subjects: 310
Study: 18314230

Group type: EXPERIMENTAL
Intervention: Diacylglycerol oil (25 g/day for 120 days)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Triacylglycerol oil (25 g/day for 120 days)
Number of subjects: 127
Study: 15780649

Group type: EXPERIMENTAL
Intervention: Lateral wedge with subtalar strapping for less than 5 hours daily (short group), n=21
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lateral wedge with subtalar strapping for 5-10 hours daily (medium group), n=20
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lateral wedge with subtalar strapping for greater than 10 hours daily (long group), n=18
Number of subjects: 81

Group type: COMPARATOR
Intervention: Subtalar strapping band without lateral wedge (placebo group), n=22
Number of subjects: 81